Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 - Test2 - elhamkhani - TriplyDB

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2

http://www.wikidata.org/entity/Q24612603

about

Thunder and lightning: immunotherapy and oncolytic viruses collide Intelligent design: combination therapy with oncolytic viruses Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Oncolytic viruses as anticancer vaccines Current issues and future directions of oncolytic adenoviruses.Impact of tumor microenvironment on oncolytic viral therapy Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape Polymeric oncolytic adenovirus for cancer gene therapy.T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Pharmacologic and chemical adjuvants in tumor virotherapy.Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?The evolving role of dendritic cells in cancer therapy.Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model New perspectives in cancer virotherapy: bringing the immune system into play.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Oncolytic virotherapy Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Oncolytic Immunotherapy for Treatment of Cancer.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Systemic virotherapy for multiple myeloma.Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide

P2860

Q24597894-5E8C35CD-1923-48C2-B349-3B86F70F03A2 Q24628227-12B3B558-A413-4483-8C13-5C9F5DBA94AE Q26750568-2662B593-A9CE-46AD-815E-F8EEDBA8034F Q27025600-D9A99916-8A13-49AC-8D5F-DBAA4598E41B Q33730705-0EDB31F7-E9B7-4A4D-9071-1A070CD7BC26 Q33895533-07522A6F-0EA2-4CC7-A4B1-F473C48CA5F1 Q33927165-5C3F4818-3B46-4968-BE6B-11EBB0C179F1 Q34059205-B3EAFAEA-6C08-40EA-8D0B-441AC92ADCFF Q34763999-228F114D-D101-429D-B381-AFC43E822B0A Q34988018-85023B22-8FDC-4ED4-ABDB-735C07C48DD1 Q35596563-49C32CA2-7B4E-4B61-9E67-F01A2E330508 Q35687743-6966DFD2-6765-4B58-9B91-876386634016 Q36321054-F00EFB1E-0931-4CF5-93FB-45282724360C Q36344901-FCA7FB79-55B4-4843-9AE2-0B6BD87047B6 Q36552580-5B4B3CB3-FB7D-4834-9CE3-778E08FC122B Q36574519-AFE2B9AE-6FF5-402C-83A6-6ED353E9A574 Q36582819-9FF99DE1-639C-40DC-BF0B-77DC5D1D4EA9 Q36890816-86AF97E9-9E26-4D2A-81AE-D0B0B2D936FE Q37459636-E646A4C0-68A2-43D3-A7B5-D2E03354767C Q37492540-906A03E2-E3FC-408D-B943-200FF8500EBF Q37513298-F83A7CEF-3470-4058-9CE0-2C8E51ECB5D3 Q37687418-15EE82D8-FB1A-4F45-B9EA-C736FDFBD141 Q37727843-B26D33C3-A764-4DEC-8EB6-60F76943A435 Q37773253-8DB78628-0178-4E08-864A-DDB0F04C39C0 Q37899223-6F7F09F3-9E17-4228-8658-A2E38FD660EB Q38008023-61EF4840-F513-4965-AC18-9329F7BFE657 Q38025263-0D6A636F-AEC8-43D7-9F79-CBC6B2945280 Q38058884-63E67E92-568B-477A-8905-1E4C5D63BA59 Q38094806-7CCBF5F7-AEDB-47C2-979F-38124BBAC52C Q38218674-CF5CEB2A-3D1D-476B-8395-E2E92F43DC7F Q38223419-9C017319-267E-4C3F-A8AD-D7AE12AEA5C3 Q38237657-91F4236D-56D7-4A3F-91A3-B50C4B61012C Q38848223-5DEF649C-0F2A-4991-84AC-6C963BF3695C Q39387174-15076F7E-691E-400E-A74B-59A790509167 Q40087770-4DF183EC-1E18-408F-BAD2-8D3CC37735F4 Q42157100-380D4B27-5B01-428F-A810-F86DECAE9E13

P2860

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2

http://www.wikidata.org/entity/Q24612603

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Improved systemic delivery of ...... g modulation and interleukin-2

@ast

Improved systemic delivery of ...... g modulation and interleukin-2

@en

Improved systemic delivery of ...... g modulation and interleukin-2

@en-gb

Improved systemic delivery of ...... g modulation and interleukin-2

@nl

type

label

Improved systemic delivery of ...... g modulation and interleukin-2

@ast

Improved systemic delivery of ...... g modulation and interleukin-2

@en

Improved systemic delivery of ...... g modulation and interleukin-2

@en-gb

Improved systemic delivery of ...... g modulation and interleukin-2

@nl

prefLabel

Improved systemic delivery of ...... g modulation and interleukin-2

@ast

Improved systemic delivery of ...... g modulation and interleukin-2

@en

Improved systemic delivery of ...... g modulation and interleukin-2

@en-gb

Improved systemic delivery of ...... g modulation and interleukin-2

@nl

P1433

Q24612603-B2D6785E-6C41-4D2B-B894-EAF9528B5D70

P1476

Q24612603-4FE68771-8F0E-4850-BCC4-8A2062EA4C74

P2093

Q24612603-12BA1FEF-AECD-4FBE-8A8C-F0CAE26D613A

Q24612603-4C27F6AF-A9CA-4738-BBC1-66B3EA7D055D

Q24612603-686851EC-8E13-43D4-A81F-ECFF8434C528

Q24612603-7EB0A31D-3C4F-4318-86A9-88EB71D59E92

Q24612603-9C147585-89DB-47DC-8E91-B39144950877

Q24612603-B08ACD8B-792C-4751-BEF7-1FEC3120EFC8

Q24612603-CFD6DA13-E20B-4808-981E-0CB0DFA6956B

P2860

Q24612603-1017407F-5A8D-4AB2-81F0-5C0F9FC1D6AE

Q24612603-132B6F7A-CF25-4977-ACA4-E4C14FEA73F4

Q24612603-1713C38E-DE3C-467E-AA0D-D1FC1A7DA418

Q24612603-270B270B-AA9A-4E6D-8A3B-079FE93ED22E

Q24612603-2B628BC4-EB98-4438-9C4E-B93D65A17519

Q24612603-388FAA45-DF6D-4BC9-A861-507493DF5475

Q24612603-3D2E345C-AF92-4CFB-8578-F2EAD07DB280

Q24612603-3D719168-B35B-419B-B786-17697BEAF896

Q24612603-3E1A16CE-00A6-4091-B4A6-FE1C1B7FB243

Q24612603-52F93786-BDAE-4839-934D-31BAA3456383

P304

Q24612603-B97BB208-0710-43C1-9AF9-4742F349C449

P31

Q24612603-4C88EAAE-57B6-4381-AD29-9628E5E3D4EA

P356

Q24612603-BF156C99-71CA-4A29-BB1B-F791E8F6C261

P407

Q24612603-3CEEDE8D-2C90-41E7-8942-1CBF1F77D069

P433

Q24612603-CE9B4063-A763-4E59-82B1-FB444A84D5B9

P478

Q24612603-3D5777E8-B5DC-4521-8EEF-A9C76F2AA8C3

P50

Q24612603-3E2AC275-C379-458D-9C59-293927C25901

Q24612603-6C2C8B8E-53DF-468E-A1A5-0C0C21949A8F

Q24612603-D66CA2C4-0200-40D9-AA5C-BC09C8CCD8FA

P577

Q24612603-B814DD0F-11EA-46CF-9B83-C00BF66DCF2B

P698

Q24612603-D1EE79C0-0711-44F7-B196-CA71880D59F5

P921

Q24612603-4e447266-abd8-4d1b-a5d5-090ec3a07141

Q24612603-7298475C-55CC-4095-B906-BA03F45BEBAC

Q24612603-ED5AC93A-A417-4299-A7EF-7BD54B28C5E4

P932

Q24612603-1DFC8A3C-7B7E-45D6-A63D-FD338F6D19A2

P356

1078-0432.CCR-08-1688

P1433

Clinical Cancer Research

P1476

Improved systemic delivery of ...... g modulation and interleukin-2

@en

P2093

Jill Thompson

http://www.w3.org/2001/XMLSchema#string

Jose Pulido

http://www.w3.org/2001/XMLSchema#string

Kevin Harrington

http://www.w3.org/2001/XMLSchema#string

Matt Coffey

http://www.w3.org/2001/XMLSchema#string

Richard G Vile

http://www.w3.org/2001/XMLSchema#string

Rosa Maria Diaz

http://www.w3.org/2001/XMLSchema#string

Timothy Kottke

http://www.w3.org/2001/XMLSchema#string

P2860

Fractalkine-mediated endothelial cell injury by NK cells

T cell receptor antagonist peptides induce positive selection

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Not all viruses are bad guys: the case for reovirus in cancer therapy.

Reovirus therapy of tumors with activated Ras pathway.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.

P304

561-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1688

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Candice L. Willmon

P577

2009-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19147761

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3046733

http://www.w3.org/2001/XMLSchema#string